Article Text

Download PDFPDF
Omalizumab for childhood asthma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Omalizumab is a humanised monoclonal antibody against immunoglobulin E (IgE). Several trials have attested to its effectiveness in the treatment of asthma. It has been postulated that because people who live in the inner city are more likely to have multiple and high allergen exposure and are more likely to show allergic sensitisation, they may be more likely to respond to anti-IgE treatment. Now a US trial (N Engl J Med 2011;364 …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.